Summary
Eli Lilly and Company (LLY) filed an 8-K on August 4, 2022, primarily to announce its financial results for the quarter ended June 30, 2022. The key information regarding these results is contained within the press release attached as Exhibit 99.1. Investors should refer to this press release for details on revenue, earnings, and any other operational or financial performance metrics for the second quarter of 2022. This filing serves as the official notification of these results, indicating that the company has met its reporting obligations. While the 8-K itself is brief and procedural, the attached press release is the critical document for understanding Lilly's performance during the reported period and its implications for the company's financial condition and future outlook.
Key Highlights
- 1The 8-K filing announces Eli Lilly's financial results for the quarter ended June 30, 2022.
- 2The detailed financial results are provided in the press release attached as Exhibit 99.1.
- 3The filing is dated August 4, 2022, with an event date of August 3, 2022.
- 4This report is being furnished and is not deemed 'filed' under Section 18 of the Exchange Act, meaning it doesn't carry the same liability as a definitive filing.
- 5The press release is incorporated by reference into Item 2.02 (Results of Operations and Financial Condition).
- 6The filing also includes Exhibit 104, the Cover Page Interactive Data File.